Melanoma patients receiving combination therapy have the highest risk of ChILI; however, the risk of new-onset ChILI in melanoma and renal cancer patients who received combination therapy and continued on anti-PD1 drops after 4.5 months of therapy. Here, PDCD1 is linked to renal carcinoma.